🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Daqing
Clinical trial register · China

Clinical Trials in Daqing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Harbin Medical University5 Xi Chen1 AstraZeneca1 Oupushifang Pharmaceutical Technology Co., Ltd.1 Rong Zhang1
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Daqing

28 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Heart Voice: Starry Journey - A Digital ACT Intervention for ASD Caregivers
NCT07319455Autism Spectrum Disorder
Harbin Medical University
Not applicable
52
Daqing
2026-11
Not yet open
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
NCT07749924Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC)
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Not yet open
Huanghou Zhixie Diwan in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
NCT07721012Patients With Irritable Bowel Syndrome With Diarrhea
Lei Yunshang Group
Phase 2
120
Beijing, Changsha, Daqing, Guangzhou, Hohhot, Lianyungang, Luoyang, Meihekou
2026-07-31
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
By invitation
A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
NCT07416344Coronary Artery Disease
Harbin Medical University
Not applicable
14,980
Daqing, Harbin, Hegang, Jiamusi, Mudanjiang, Qiqihar, Shuangyashan, Suihua
2026-04-27
Active, closed
RBD5044 in Chinese Participants With Hypertriglyceridemia
NCT07587788Hypertriglyceridemia
Ribotek Biopharmaceuticals (Shandong) Co., Ltd
Phase 2
40
Daqing, Harbin, Luoyang, Jingzhou, Nanyang, Yuncheng, Beijing
2026-02-28
Recruiting
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
NCT07520565AIS
Biocells (Beijing) Biotech Co.,Ltd
Phase 3
1,112
Hengshui, Daqing, Nanyang, Meihekou, Shenyang, Xianyang, Linyi, Linfen
2026-01-19
Recruiting
Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
NCT07279493Acute Ischemic Stroke
Kunming Pharmaceuticals, Inc.
Phase 2
300
Beijing, Shenzhen, Cangzhou, Hengshui, Daqing, Anyang, Nanyang, Xuzhou
2025-11-22
Not yet open
A Phase III Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
NCT07146126Seasonal Allergic Rhinitis, SAR
Prime Gene Therapeutics Co., Ltd.
Phase 3
600
Beijing, Lanzhou, Baoding, Cangzhou, Langfang, Shijiazhuang, Daqing, Harbin
2025-09-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Active, closed
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
NCT06494241Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
AstraZeneca
Observational
1,000
Anning, Anqing, Changzhi, Daqing, Dazhou, Dazhu, Dingzhou, Ganzhou
2024-11-22
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
NCT06568471Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Hasten Biopharmaceutical Co., Ltd.
Phase 3
210
Beijing, Guangzhou, Shijiazhuang, Daqing, Changsha, Nanchang, Binzhou, Heze
2024-11-16
Recruiting
Construction of a Risky Sexual Behaviour Intervention Programme for College Students Based on BCW Theory
NCT06435234Unsafe Sex
Rong Zhang
Not applicable
40
Daqing
2024-09-29
Recruiting
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression
NCT06708156Myopia, Myopia Progression
Oupushifang Pharmaceutical Technology Co., Ltd.
Phase 3
606
Hefei, Xuancheng, Lanzhou, Liuzhou, Nanning, Guiyang, Zunyi, Daqing
2024-06-15
Recruiting
Effects of Appropriate Technology for Home-based Rehabilitation in Patients With Post-stroke Physical Dysfunction
NCT06437587Stroke
Xi Chen
Not applicable
72
Daqing
2024-06-01
Recruiting
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
NCT06685978Hyperplasia of Mammary Glands
Tasly Pharmaceutical Group Co., Ltd
Phase 3
430
Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing
2024-04-26
Recruiting
Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)
NCT06365502Acute Coronary Syndrome (ACS)
Harbin Medical University
Not applicable
1,860
Beijin, Zunyi, Daqing, Harbin, Jiamusi, Mudanjiang, Zhengzhou, Wuhan
2024-04-16
Recruiting
ACT Combined Yoga for Parental Burnout in Parents with Autistic Children
NCT06348992Autism Spectrum Disorder
Harbin Medical University
Not applicable
60
Daqing
2023-09-01
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925ST Elevation Myocardial Infarction
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
300
Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an
2023-04-06
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals
Phase 3
14,012
Guangzhou, Nanning, Cangzhou, Shijiazhuang, Tangshan, Xingtai, Daqing, Harbin
2023-03-09
Recruiting
Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort
NCT05862103Acute Myocardial Infarction, Adverse Event
Yu Bo
Observational
15,000
Beijing, Guangzhou, Nanning, Shijiazhuang, Daqing, Zhengzhou, Nanjing, Nanchang
2022-12-21
Active, closed
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT05581303Atherosclerotic Cardiovascular Disease
Amgen
Phase 3
7,297
Beijing, Guangzhou, Huizhou, Nanning, Daqing, Harbin, Nanyang, Changsha
2022-12-14
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma
Phase 3
9,541
Beijing, Bengbu, Changde, Changzhou, Chifeng, Daqing, Foshan, Guangzhou
2022-02-07
Recruiting
Effects of Prior Induced Termination of Pregnancy on Complications and Pregnancy Outcomes.
NCT04183829Reproductive Health, Abortion
National Research Institute for Family Planning, China
Observational
20,000
Zhongshan, Zhangjiakou, Daqing, Changzhou, Yangzhou, Hohhot, Qingdao, Zaozhuang
2019-06-01
Active, closed
Sympathetic Mapping/ Ablation of Renal Nerves Trial
NCT02761811Hypertension
SyMap Medical (Suzhou), Ltd.
Not applicable
220
Beijing, Chongqing, Shenzhen, Shijiazhuang, Daqing, Wuhan, Nanjing, Xuzhou
2016-06-30
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/daqing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Daqing.

How many clinical trials are recruiting in Daqing?

15 of the 28 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 7 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Daqing), 28 studies
PhaseStudiesRecruitingShare
Phase 310535.7%
Not applicable9532.1%
Observational4214.3%
Phase 24214.3%
Phase 4113.6%

Most active sponsors

Lead sponsors with the most studies (Daqing)
Lead sponsorStudiesRecruiting
Harbin Medical University53
Affiliated Hospital of Changchun University of Chinese Medicine10
Amgen10
AstraZeneca10
Biocells (Beijing) Biotech Co.,Ltd11
Eli Lilly and Company11
Hasten Biopharmaceutical Co., Ltd.11
Janssen Research & Development, LLC10
Kunming Pharmaceuticals, Inc.11
Lei Yunshang Group10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.